SCHEMBL8970567

SCHEMBL8970567

CCCCOC1CCC(C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PPP5C P53041 1/20 0.43
EPHX2 P34913 1/20 0.40
S1PR5 Q9H228 10/20 0.37
S1PR1 P21453 6/20 0.37
S1PR3 Q99500 4/20 0.36
LIPC P11150 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NAAA Q02083 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8969446 0.95 EPHX2 (0.45) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL8970376 0.93 EPHX2 (0.44) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL8970509 0.93 EPHX2 (0.44) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL8970086 0.93 EPHX2 (0.44) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL8969164 0.93 EPHX2 (0.44) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL27810373 0.90 PPP5C (0.41) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL27810374 0.90 PPP5C (0.41) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL849072 0.89 PPP5C (0.42) PPP5CEPHX2S1PR5S1PR1S1PR3
SCHEMBL8969589 0.89 PPM1B (0.36) PPP5CEPHX2S1PR5
SCHEMBL2606682 0.87 PPP5C (0.46) PPP5CEPHX2S1PR5S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206707-B1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-07-23 EP disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed
EP-0376294-B1 Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions HITACHI LTD (JP) 1996-03-13 EP disclosed
US-5370821-A Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-12-06 US disclosed
US-5269965-A Optically active compounds, liquid crystal compositions comprising said compounds and liquid crystal optical modulators using said compositions TAKEDA CHEMICAL INDUSTRIES (JP) 1993-12-14 US disclosed
EP-0376294-A1 Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions HITACHI, LTD. (JP) 1990-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 PPP5C 1047/4885EPHX2 3595/4885S1PR5 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.